Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2018
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2018
SUMMARY
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The latest report Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Sphingosine-1-phosphate receptor 1 (S1P receptor) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.
The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 4, 6, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Cardiovascular, Dermatology, Musculoskeletal Disorders and Oncology which include indications Crohn's Disease (Regional Enteritis), Multiple Sclerosis, Rheumatoid Arthritis, Ulcerative Colitis, Autoimmune Disorders, Relapsing Remitting Multiple Sclerosis (RRMS), Inflammation, Psoriasis, Relapsing Multiple Sclerosis (RMS), Secondary Progressive Multiple Sclerosis (SPMS), Arthritis, Atopic Dermatitis (Atopic Eczema), Cardiovascular Disease, Cerebral Aneurysms, Colitis, Dermatomyositis, Encephalomyelitis, Graft Versus Host Disease (GVHD), Inflammatory Bowel Disease, Kidney Transplant Rejection, Plaque Psoriasis (Psoriasis Vulgaris), Primary Biliary Cirrhosis, Rett Syndrome, Skin Ulcers, Stroke and Systemic Lupus Erythematosus.
Furthermore, this report also reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The latest report Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Sphingosine-1-phosphate receptor 1 (S1P receptor) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.
The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 4, 6, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Cardiovascular, Dermatology, Musculoskeletal Disorders and Oncology which include indications Crohn's Disease (Regional Enteritis), Multiple Sclerosis, Rheumatoid Arthritis, Ulcerative Colitis, Autoimmune Disorders, Relapsing Remitting Multiple Sclerosis (RRMS), Inflammation, Psoriasis, Relapsing Multiple Sclerosis (RMS), Secondary Progressive Multiple Sclerosis (SPMS), Arthritis, Atopic Dermatitis (Atopic Eczema), Cardiovascular Disease, Cerebral Aneurysms, Colitis, Dermatomyositis, Encephalomyelitis, Graft Versus Host Disease (GVHD), Inflammatory Bowel Disease, Kidney Transplant Rejection, Plaque Psoriasis (Psoriasis Vulgaris), Primary Biliary Cirrhosis, Rett Syndrome, Skin Ulcers, Stroke and Systemic Lupus Erythematosus.
Furthermore, this report also reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)
- The report reviews Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Overview
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Companies Involved in Therapeutics Development
Actelion Pharmaceuticals Ltd
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Celgene Corp
GlaxoSmithKline Plc
Idorsia Pharmaceutical Ltd
LG Chem Ltd
Mitsubishi Tanabe Pharma Corp
Novartis AG
Sanofi
Sun Pharma Advanced Research Company Ltd
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Drug Profiles
AKP-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amiselimod hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-0028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-4058 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-173717 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBP-307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenerimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-1050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etrasimod arginine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fingolimod hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LC-510255 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIBR-0213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ozanimod hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ponesimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-247799 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCD-044 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
siponimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize S1P1 for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-968 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Dormant Products
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Discontinued Products
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Product Development Milestones
Featured News & Press Releases
May 11, 2018: Novartis Announces FDA Approval of Gilenya as the First Disease-modifying Therapy for Pediatric Relapsing Multiple Sclerosis
Apr 24, 2018: New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting
Apr 20, 2018: New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients
Mar 23, 2018: Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
Mar 19, 2018: Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis
Feb 27, 2018: Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis
Jan 22, 2018: Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City
Dec 18, 2017: Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Nov 10, 2017: Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis
Nov 09, 2017: Ozanimod Successful in Clinical Trials for Multiple Sclerosis
Oct 28, 2017: Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a
Oct 28, 2017: Efficacy and Safety Results from Second Phase III Trial (RADIANCE Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Oct 27, 2017: Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Oct 25, 2017: Novartis confirms leadership in multiple sclerosis with scientific advancements and new data presented at ECTRIMS
Oct 25, 2017: Novartis Presents New Data on Siponimod at ECTRIMS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Overview
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Companies Involved in Therapeutics Development
Actelion Pharmaceuticals Ltd
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Celgene Corp
GlaxoSmithKline Plc
Idorsia Pharmaceutical Ltd
LG Chem Ltd
Mitsubishi Tanabe Pharma Corp
Novartis AG
Sanofi
Sun Pharma Advanced Research Company Ltd
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Drug Profiles
AKP-11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amiselimod hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-0028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-4058 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-173717 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBP-307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenerimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-1050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etrasimod arginine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fingolimod hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LC-510255 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NIBR-0213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ozanimod hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ponesimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-247799 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCD-044 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
siponimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize S1P1 for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-968 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Dormant Products
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Discontinued Products
Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Product Development Milestones
Featured News & Press Releases
May 11, 2018: Novartis Announces FDA Approval of Gilenya as the First Disease-modifying Therapy for Pediatric Relapsing Multiple Sclerosis
Apr 24, 2018: New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting
Apr 20, 2018: New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients
Mar 23, 2018: Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
Mar 19, 2018: Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis
Feb 27, 2018: Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis
Jan 22, 2018: Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City
Dec 18, 2017: Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Nov 10, 2017: Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis
Nov 09, 2017: Ozanimod Successful in Clinical Trials for Multiple Sclerosis
Oct 28, 2017: Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a
Oct 28, 2017: Efficacy and Safety Results from Second Phase III Trial (RADIANCE Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Oct 27, 2017: Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting
Oct 25, 2017: Novartis confirms leadership in multiple sclerosis with scientific advancements and new data presented at ECTRIMS
Oct 25, 2017: Novartis Presents New Data on Siponimod at ECTRIMS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Actelion Pharmaceuticals Ltd, H2 2018
Pipeline by Arena Pharmaceuticals Inc, H2 2018
Pipeline by Astellas Pharma Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Boston Pharmaceuticals Inc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
Pipeline by LG Chem Ltd, H2 2018
Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Sanofi, H2 2018
Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Actelion Pharmaceuticals Ltd, H2 2018
Pipeline by Arena Pharmaceuticals Inc, H2 2018
Pipeline by Astellas Pharma Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Boston Pharmaceuticals Inc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Celgene Corp, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
Pipeline by LG Chem Ltd, H2 2018
Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Sanofi, H2 2018
Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Actelion Pharmaceuticals Ltd
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Celgene Corp
GlaxoSmithKline Plc
Idorsia Pharmaceutical Ltd
LG Chem Ltd
Mitsubishi Tanabe Pharma Corp
Novartis AG
Sanofi
Sun Pharma Advanced Research Company Ltd
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Actelion Pharmaceuticals Ltd
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Boston Pharmaceuticals Inc
Bristol-Myers Squibb Co
Celgene Corp
GlaxoSmithKline Plc
Idorsia Pharmaceutical Ltd
LG Chem Ltd
Mitsubishi Tanabe Pharma Corp
Novartis AG
Sanofi
Sun Pharma Advanced Research Company Ltd
